Cel Sci (CVM) EPS (Basic) (2010 - 2026)

Cel Sci (CVM) posted EPS (Basic) of -$5.29 for Q1 2026, down 7.92% sequentially from -$4.9 in Q4 2025, and up 51.77% YoY from -$3.49 in Q1 2025.

Cel Sci (CVM) EPS (Basic) (2010 - 2026) Analysis & Trends

Cel Sci has reported EPS (Basic) for 17 years, with the latest figure at -$5.29 in Q1 2026.

Quarterly EPS (Basic) rose 51.77% year-over-year to -$5.29 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$21.98 (up 51.72% YoY) and the FY2025 annual result came in at -$33.89, up 28.33% from the prior year.
EPS (Basic) eased to -$5.29 in Q1 2026 per CVM's latest filing, from -$4.9 in the prior quarter.
Over five years, EPS (Basic) peaked at -$4.15 in Q4 2023 and troughed at -$11.18 in Q4 2024.
A 5-year average of -$6.78 and a median of -$5.74 in 2023 frame the typical range for EPS (Basic).
The sharpest annual moves came in 2024 and 2025: EPS (Basic) tumbled 169.19% in 2024, then soared 56.13% in 2025.
Over 5 years, EPS (Basic) stood at -$5.54 in 2022, then gained by 25.07% to -$4.15 in 2023, then slumped by 169.19% to -$11.18 in 2024, then jumped by 56.13% to -$4.9 in 2025, then decreased by 7.92% to -$5.29 in 2026.
According to Business Quant data, EPS (Basic) over the past three periods registered -$5.29, -$4.9, and -$8.14 for Q1 2026, Q4 2025, and Q3 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EPS (Basic) (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	4.34
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	12.62
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	7.59
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	-1.96
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	2.12
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	1.23
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	-0.72
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	-0.06
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	0.18
10	Cel Sci	2.12 Mn	-4.42 Mn	-	-3.82

Download Data